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Abstract
Objectives: Despite safe handling guidelines published by several groups, health care worker 
exposure to hazardous drugs continues to occur due to suboptimal engineering controls and low 
use of protective equipment. Simple, multi-target and specific analytical methods are needed so 
that acute exposures to these drugs in the workplace can be assessed rapidly. Our aim was to 
develop an analytical method for simultaneous detection and quantification of widely used cancer 
drugs to rule out accidental acute chemotherapy exposures in health care workers.
Methods: We examined the feasibility of alternate high-performance liquid chromatographic-
tandem mass spectrometry methods to simultaneously detect eighteen chemotherapy analytes in 
plasma and urine. The linear concentration ranges tested during assay development were 0.1–50 
ng/mL. After development of a multi-analyte assay protocol, plasma samples (n = 743) from a 
multi-center cluster-randomized clinical trial (n = 12 sites) of an hazardous drug educational 
intervention were assayed. Confirmatory assays were performed based on the individual acute-
spill case-histories.
Results: An innovative HPLC-multiple reaction monitoring-information dependent acquisition-
enhanced production ion (MRM-IDA-EPI) analytical method was developed to simultaneously 
detect: cytarabine, gemcitabine, dacarbazine, methotrexate, topotecan, mitomycin, pemetrexed, 
irinotecan, doxorubicin, vincristine, vinblastine, ifosamide, cyclophosphamide, vinorelbine, 
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bendamustine, etoposide, docetaxel, and paclitaxel. The retention times ranged from 4 min to 13 
min for the analytical run. The limit of detection (MRM-IDA-EPI) and limit of quantitation 
(MRM) was 0.25 ng/mL and 0.1 ng/mL, respectively for most analytes. No detectable plasma 
concentrations were measured at baseline, post-intervention and in cases of documented acute 
spills. Use of a secondary tandem mass spectrometry approach was able to successfully rule out 
false positive results.
Conclusions: Development of a sensitive high-throughput multi-analyte cancer chemotherapy 
assay is feasible using an MRM-IDA-EPI method. This method can be used to rapidly rule out 
systemic exposure to accidental acute chemotherapy spills in health care workers.
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Introduction
Cancer chemotherapy agents are hazardous drugs (HDs) that pose significant occupational 
health risks to clinical personnel from the point of procurement to administration. In 2004, 
the National Institute for Occupational Safety and Health (NIOSH) issued an alert that 
summarized these health risks, such as skin rashes and adverse reproductive outcomes 
(including infertility, spontaneous abortions, and congenital malformations), and risk for 
leukemia and other cancers posed by HD exposures.1 An estimated eight million health care 
workers are potentially exposed to HDs in the United States each year.2 This risk potential 
has culminated in numerous recommendations from societies and regulatory bodies, which 
include the centralization of the preparation of cytotoxic drugs in dedicated areas with safety 
hoods and using personal protective equipment (PPE).3–7
Recently, the United States Pharmacopeia (USP) issued an enforceable standard 
(USP<800>) for handling HDs in health care settings that will impact the storage, 
transportation, preparation and administration of these agents. This general chapter will be 
combined with USP<795> and USP<797> general chapters to form a more comprehensive 
compounding standard by 1 December 2019.7 Currently, USP standards are recognized in 
several provisions of the federal Food, Drug, and Cosmetic Act (FDCA) and regulatory 
policies of several state boards of pharmacy. California is the first state to require full 
compliance with USP<800>. As a consequence, enforcement of these standards by the US 
Food and Drug Administration, Center for Medicare & Medicaid Services and The Joint 
Commission are expected. This single-source standard serves to protect pharmacists, 
technicians, nurses, physicians, physician assistants, home health care workers, 
veterinarians, veterinary technicians and any other health care workers who access facilities 
where HDs are prepared and administered. This standard does not currently recommend 
biological monitoring with the exception that it may be helpful as a follow-up to an acute 
HD spill.
Over 18 million cancer chemotherapy doses are administered annually in the US alone, 
which places oncology nurses at an exceptional risk for acute HD spill exposure.8 Statewide 
surveys have revealed that one out of six ambulatory care nurses reported skin or eye 
Shu et al. Page 2
J Oncol Pharm Pract. Author manuscript; available in PMC 2021 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
exposure to chemotherapy in the past year.9 Several studies have developed analytical 
methods demonstrating health care worker biological exposure to cancer chemotherapy 
during preparation and administration of the agent.10–29 We previously documented 
measurable pemetrexed, docetaxel, and cisplatin plasma concentrations in a sample of nurses 
and pharmacists who consented to participating in a six-month prospective study of acute 
HD spills. We subsequently performed a multicenter cluster randomized controlled trial to 
compare an educational module on HD handling to the same educational module plus survey 
feedback and biological data from participants.30 Biological data included plasma sampling 
at baseline and post-intervention assessment, as well as with the occurrence of any reported 
drug spill during the study to assay for presence of the HD. Given the breadth of potential 
HD spills, we focused on assay development of the 20 most widely used cancer 
chemotherapy agents in ambulatory oncology settings. Herein, we report on the development 
of an innovative multi-analyte assay and the results of biomonitoring as a follow-up to acute 
spills of cancer chemotherapy drugs. The presented analytical approach supports the 
provision of feedback to health care workers who experience an accidental spill of widely 
used chemotherapy agents.
Methods
Materials and reagents
Dacarbazine (DACA) was purchased from Tokyo Chemical Industry Co. (Portland, OR, 
USA). Paclitaxel (TAX) and docetaxel (DOCE) were purchased from Fisher Scientific 
(Pittsburgh, PA, USA). Ifosfamide (IF), cyclophosphamide (CP), bendamustine (BEN), 
irinotecan (IRI), topotecan (TOP), etoposide (ETOP), vincristine (VCR), vinblastine (VBL), 
vinorelbine (VIN), methotrexate (MTX), pemetrexed (PTR), gemcitabine (GCA), 
fludarabine (FLD), doxorubicin(DOXO) and mitomycin (MIT) were purchased from Sigma 
Chemical Co. (St Louis, MO, USA). Standard purity was ≥98% for all analytes. Irinotecan-
d10 (IS1), doce-taxel-d9 (IS2), bendamustine-d6 (IS3), topotecan-d6 (IS4) were used as 
internal standards (IS). All ISs were obtained from Santa Cruz Biotechnology (Dallas, TX, 
USA). Acetonitrile, methanol and formic acid were HPLC-MS-grade and were obtained 
from Fisher Scientific (Pittsburgh, PA, USA). Deionized water was obtained from a Milli-Q 
Plus system (Millipore, Bedford, MA, USA). Control human plasma samples from pooled 
donors were purchased from Valley Biomedical (Winchester, VA, USA).
Preparation of analyte standard solutions
Individual stock solutions of the standards and internal standards, all at 1.0 mg/mL, were 
prepared by dissolving appropriate amounts of the analyte in dimethyl sulfoxide (DMSO). 
This solvent was selected due to nonpolar analytes such as paclitaxel and in order to 
maintain potency of the stock solutions. These solutions were found to be stable for at least 
six months when stored in the dark and refrigerated (2–8°C) conditions. Composite working 
standard solutions of all analytes were prepared by combining the above solutions and 
diluting with methanol:acetonitrile (1:1, v:v) to a final concentration of 20 μg/mL. The 
internal standard working solutions were prepared with methanol: acetonitrile (1:1) and 
0.1% formic acid. For the method limits evaluation (limits of detection, selectivity, method 
validation), composite calibration working solutions were prepared by diluting the above 
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solutions with blank plasma to obtain analyte concentrations suitable for the experiments. 
When unused, stock solutions were stored at −80°C, while working solutions of standards 
and internal standards at −20°C. The working standard mixtures were freshly prepared 
before use.
Sample extraction procedure
An aliquot of 80 μL plasma samples were mixed with 120 μL of internal standard solution, 
then shaken for 10 min and centrifuged at 4000 r/min for 10 min at 4°C. The supernatant 
was transferred to a 96-well plate and 30 μL was injected for LC-MS analysis.
Liquid chromatography and mass spectrometry
High-performance liquid HPLC–MS/MS analyses were performed in a system consisting of 
a Shimadzu Nexera XR ultra high-performance liquid chromatograph system (Shimadzu 
Scientific Instruments, Columbia, MD, USA), connected in series to a 5500 QTRAP hybrid 
triple quadrupole linear ion trap mass spectrometer equipped with a TurboIonSpray source 
(Sciex, Redwood City, CA, USA), operated in the positive electrospray ionization mode 
(ESI). The analytical instrumentation was controlled by Analyst 1.6.2 (Sciex).
HPLC separation of the analytes was performed with a 150 mm × 4.6 mm Xbridge C18 
column (3.5 μm particle size) (Waters Corporation, 34 Maple Street Milford, MA, USA) and 
a mobile phase consisting of ACN and water, both acidified with 0.1% formic acid, at a flow 
rate of 0.7 mL/min. The initial conditions (2% ACN) were maintained for 2 min, then the 
following gradient elution scheme was used: 2–5% A in 1 min, 5–20% A in 1 min, 20–70% 
A in 7 min, and then to 95% in the following 0.1 min, which was held for a further 2.9 min; 
finally, the column was equilibrated for 3 min to the initial conditions. This gradient 
provided a chromatographic analysis time of 17 min.
MS/MS analyses were performed in the scheduled MRM and MRM-IDA-EPI mode. A total 
of 22 transitions in positive mode were monitored with an MRM pause time of 3 ms for the 
18 analytes and 4 ISs. This pause time refers to the brief period of time for the mass 
spectrometer to reset between transients. The Scheduled MRM™ algorithm was used with 
an MRM detection window of 60 s and a target scan time of 0.7 s in Analyst®1.6 Software. 
For increased confidence in compound identification, information dependent acquisition 
(IDA) criteria were employed in order to automatically trigger the acquisition of EPI scans 
for any compounds that were detected by the MRM scans. EPI spectra at a scan speed of 
10,000 Da/s were acquired using a dynamic fill time for optimal MS/MS quality, and 
generated using standardized collision energy (CE) of 40 V with collision energy spread 
(CES) of 15 V to ensure a characteristic MS/MS pattern independently of the compound’s 
fragmentation efficiency. All source and instrument parameters for the monitored analytes 
were tuned by infusing each single standard solution at a concentration of 0.5 μg/mL by a 
syringe pump (flow rate 10 μL/min). All the source parameters were checked (and revised as 
necessary) in flow injection analysis with the same chromatographic conditions (flow and 
solvent composition). Nitrogen was used as curtain, nebulizer, drying and collision gas (15, 
50, 50 and “medium,” respectively, manufacturer’s units); drying gas temperature was set at 
450°C. The most important MS parameters for MRM and EPI acquisition of the 18 target 
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compounds are summarized in Table 2. The limits of detection (LOD) and quantitation 
(LOQ) were defined as the concentrations yielding signal intensity 3 and 10 times the 
background value, respectively. The LOQ is often either equivalent to LOD or a much 
higher concentration. However, in this particular study the assessment of LOQ and LOD 
were based on two different methods. The LOD was based on MRM-IDA-EPI scan, while 
the LLOQ was based on MRM scan. Because the LOD is based on an IDA process, the 
sensitivity is lower than that of the conventional MRM scan.
Clinical trial plasma sample handling and processing
A four-year cluster randomized controlled trial known as the Drug Exposure Feedback and 
Education for Nurses’ Safety (DEFENS) study was conducted at 12 cancer centers in the 
US. Specific information regarding the clinical trial design, conceptual framework, study 
measures, spill reporting and plasma sampling has been published previously.30 In brief, 
participants provided blood for plasma sampling at baseline, after the educational 
assessment and if they experienced a chemotherapy drug spill. Sampling was performed 2 h 
after the spill with collection of 5 mL of blood in heparinized tubes. For cases with 
documented spill events, a second blood sample was collected 24 h after the first one. 
Plasma was harvested after centrifugation of the blood at 1000–2000 × g at 4°C. Plasma 
samples were stored frozen at −20°C or lower and shipped the next day on dry ice from the 
study site to the University of Michigan, Pharmacokinetic Core laboratory. Samples were 
analyzed in batches during the study period. Details regarding the spill event were 
completed using a brief report mechanism submitted by participants through a secure 
website. This report detailed the specific agent associated with the spill, time and date of 
occurrence, estimated quantity of spill, body areas exposed to the HD and estimated duration 
of exposure.
Results
This study focused on 20 HDs that are the most commonly administered chemotherapy 
agents in ambulatory oncology settings with chemical properties suitable for analysis. The 
developed LC-MS/MS method allowed the simultaneous detection of 18 of them on the 
positive ionization mode. Unfortunately, the method could not be extended to two agents, 
fludarabine and fluorouracil because they had stronger responses in the negative ionization 
mode while all other agents were best ionized in the positive mode. In order to exclude a 
cross contamination of the internal standard (IS), deuterated compounds were chosen: 
toptecan-d6, irinotecan-d10, bendamustine-d6 and docetaxel-d9 were used as IS for those 
ADs with similar retention time (RT). Details of the optimization approach are provided 
below.
Optimization of HPLC-MS/MS multi-target screening method
The HPLC method was optimized to enable best separation of 18 ADs in 13 min (17 min 
including the column reconditioning). The unresolved drugs presented different scan events 
in MRM mode. A typical chromatogram, obtained from the analysis of a calibration sample 
with 50 ng/mL of each analyte, 10 ng/mL for IS1 and IS4 and 100 ng/mL for IS2 and IS3 is 
shown in Figure 1. The ESI–MS/MS conditions were optimized for each analyte after 
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infusion of individual standard solutions (500 ng/mL). The positive ESI mode provided 
higher signal intensity for the 18 HDs selected. The positive/negative ion-switching method 
had been tested for monitoring those 18 HDs together with fludarabine and fluorouracil in 
negative ESI mode, but the other analytes’ signal intensity dropped dramatically (data not 
shown). As a consequence, fludarabine and fluorouracil were excluded in favor of 
maintaining higher sensitivity to other agents in the panel (Table 1).
The goals of HPLC-MS/MS optimization method were to obtain the most sensitivity by 
increasing the dwell time, while diminishing the total scan time. Thus, the so-called 
Scheduled MRM™ algorithm was adopted. The Scheduled MRM™ algorithm used 
knowledge of the retention time (RT) of each analyte so that each MRM transition was only 
monitored using a short time window. At any one point in time, the numbers of concurrent 
MRM transitions are significantly reduced, resulting in much higher duty cycles for each 
analyte. The software calculated the maximum dwell times for the co-eluting compounds 
while still maintaining the desired cycle time for the best signal-to noise ratio, accuracy and 
reproducibility by maintaining the same, or even improving the number of points across the 
peak. As a result, Scheduled MRM™ allowed the monitoring of many more MRM 
transitions in a single acquisition without compromising data quality.
Despite the high selectivity of MRM detection, we identified a risk of false positive findings 
due to interfering matrix signals. As a consequence a second MRM was monitored per 
analyte and the ratio of quantifier to qualifier transition was calculated for each unknown 
sample and compared to the MRM ratio of standards for identification. Previous reports 
suggest that relying only on MRM ratios for identification can result in a significant number 
of false positive results for compound identification, especially if the targeted analytes have 
a low fragmentation efficiency (many low intensity product ions).31–33 The sensitivity can 
be dramatically decreased if both quantifier and qualifier transitions are applied in the same 
run. Thus, only quantifier transitions were applied in the present study. But for improved 
accuracy, identification can be performed using full scan MS/MS experiments and 
comparison of the unknown with a standard spectrum. Therefore, dependent MS/MS spectra 
were acquired in the EPI mode of the QTRAP® 5500 system after being triggered from a 
Scheduled MRM™ IDA survey scan. The rapidly collected high-quality MS/MS data was 
used to increase the confidence of detection. Once any HD residue is detected and confirmed 
by the MS/MS data, the MRM survey scan data can be used for quantification.
Linearity and sensitivity
The developed method was found to be linear over the studied concentration range for all 
compounds (correlation coefficient 0.99266 to 0.99853). The calculated LODs by MRM-
IDA-EPI scan and LOQs by MRM scan ranged from 0.10 to 10.0 ng/mL and from 0.10 
to1.00 ng/mL in plasma, from 1.00 to 5.00 ng/mL and from 0.10 to 1.00 ng/mL in urine 
respectively, as shown in Table 2.
Clinical trial plasma results
A total of 743 plasma samples were assayed from 378 unique participants from 12 centers 
over the sampling period. There were 132 kits deployed to assess spills reported during this 
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period and 64 participants were sampled on the day of spill or within 24 h post-exposure. 
The compounds by frequency of exposure were paclitaxel (32.6%), doxorubicin (13.5%), 
etoposide (13.5%), gemcitabine (11.5%), bendamustine (11.5%), docetaxel (9.6%), 
irinotecan (5.7%), and cyclophosphamide (2.0%). All plasma sample measurements were 
below the lower limit of detection as outlined in Table 2. Plasma samples considered to be 
positive were ruled out as false positive and excluded by further comparison of the MS/MS 
data against the analytical standards.
Discussion
Cancer chemotherapy regimens that were traditionally administered in the inpatient setting 
are increasingly being administered in the ambulatory and home settings. This transition 
reduces costs to patients and the health care organization while improving patient 
satisfaction with the care that is received. In the US, approximately 23 million adult patient 
visits occur annually for chemotherapy, of which 84% are delivered primarily by nurses in 
the ambulatory setting. We previously conducted a statewide survey of oncology nurses to 
examine the likelihood of self-reported accidental exposure to cancer chemotherapy. We 
specifically sought to understand the influence of practice environment, nursing workload, 
and safety standards on this exposure risk. Skin or eye exposures to cancer chemotherapy 
were reported in 16.9% of nurses surveyed and the likelihood of exposure was related to 
staffing and resources as well as chemotherapy dose verification by another nurse. These 
findings highlighted the need for a system to provide definitive feedback to nurses about the 
systemic exposure risk associated with acute chemotherapy spills. The issuance of the 
USP<800> standard implies that a larger number of institutions will have to come under 
compliance with health safety protections for a large pool of health care workers who handle 
HDs.
Most health care systems are unlikely to have the resources or sample numbers necessary to 
establish their own analytical assays to provide definitive risk assessment when an acute 
spill occurs. Most studies that have reported systemic exposures to acute spills have relied 
on analytical methods that monitored one or a handful of analytes at the same time.
12,14,16,17,22,24,28
 However, health care workers within a setting can be exposed to a 
multitude of HDs in a given day. Centralized analytical laboratories are also unlikely to have 
the throughput and technical staff to manage sample assay requests for these acute spill 
events for individual analyte assessments. As a consequence, development of a multi-analyte 
platform represents a necessary cost-effective solution to address this challenge of sample 
assay for a large health care network or statewide initiative centered on definitive risk 
assessment. Current analytical methods that have been developed to monitor multiple HDs 
require tedious sample preparation that hinders feasibility of time-sensitive biological 
monitoring.17,23,29 We demonstrated the ability to rapidly and reliably measure 18 widely 
used cancer chemotherapy drugs in plasma using a simplified sample processing method and 
state-of-the-art mass spectrometry analytical techniques.
This analytical approach was used to screen and quantify cancer chemotherapy in a large 
cohort of nurses at baseline and in participants exposed to a spill. Fortunately, no cancer 
chemotherapy concentrations were detectable in plasma implying: (1) a low likelihood of 
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cutaneous absorption and/or (2) cutaneous absorption with limited distribution into systemic 
circulation. In addition, most participating sites employed engineering controls, including 
biological safety cabinets for compounding and closed system transfer devices during drug 
preparation and administration. Our previously published trial results suggest that personal 
protective use was suboptimal at baseline and did not improve with study interventions.30 
This unchanged low use of PPE implies that either a low potential for cutaneous absorption 
or cutaneous absorption with limited systemic distribution most likely accounted for 
undetectable plasma concentrations of these cancer chemotherapy agents. However, these 
findings are limited to acute spill based assessment of parent compounds that may not reflect 
chronic cancer chemotherapy exposures detectable through surrogate analytes of exposure 
such as metabolites.
Conclusions
Definitive risk assessment through biological sampling is a relevant consideration for health 
care workers’ who handle HDs such as chemotherapy. Since workers within a health care 
facility are likely to be exposed to multiple drugs, cost- and time-saving procedures for 
simultaneous analysis of different compounds are required. In the current study, the 
combination of HPLC and scheduled MRM-IDA-EPI mass spectrometric method permitted 
analysis of 18 HDs in a single chromatographic run. The present method focuses not only on 
the quantification but also on the confident detection of the trace HD residue in plasma 
samples, to eliminate false positive results. Since there are no guidelines for biologic 
exposure or acceptable intake and exposure limits set for HDs,25,34 tedious, cost- and time-
consuming LC-MS methods for quantification are not justified. The HDs monitoring 
methodology described here is simple, cost- and time-saving. Moreover, the collected 
MS/MS data enable detection of HDs more reliably, which can inform a feasible approach to 
definitive risk assessment of HDs.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of 
this article: This paper was supported by grant number 1 R01 OH 010582, funded by the National Institute for 
Occupational Safety and Health, Centers for Disease Control and Prevention. Its contents are solely the 
responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control 
and Prevention or the Department of Health and Human Services.
References
1. Burroughs GE CT, McDiarmid MA, Mead KR, et al. Preventing occupational exposures to 
antineoplastic and other hazardous drugs in health care settings. National Institute for Occupational 
Safety and Health 2004; NIOSH publication number 2004–165.
2. Polovich M. Safe handling of hazardous drugs. Online J Issues Nurs 2004; 9: 6.
3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. 
Am J Health Syst Pharm 2006; 63: 1172–1193.
4. Neuss MN, Polovich M, McNiff K, et al. 2013 updated American Society of Clinical Oncology/
Oncology Nursing Society chemotherapy administration safety standards including standards for the 
safe administration and management of oral chemotherapy. J Oncol Pract 2013; 9: 5 s–13 s.
5. Polovich M. Safe handling of hazardous drugs. 2nd ed. Pittsburgh: Oncology Nursing Society, 2011.
6. Polovich M, Olsen MM and LeFebvre KB. Chemotherapy and biotherapy guidelines and 
recommendations for practice, 4th ed. Pittsburgh: Oncology Nursing Society, 2014.
Shu et al. Page 8
J Oncol Pharm Pract. Author manuscript; available in PMC 2021 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Walton AL, Eisenberg S and Friese CR. Hazardous drugs: legislative and regulatory efforts to 
improve safe handling. Clin J Oncol Nurs 2017; 21: 254–256. [PubMed: 28315540] 
8. Boiano JM, Steege AL and Sweeney MH. Adherence to safe handling guidelines by health care 
workers who administer antineoplastic drugs. J Occup Environ Hyg 2014; 11: 728–740. [PubMed: 
24766408] 
9. Boiano JM, Steege AL and Sweeney MH. Adherence to precautionary guidelines for compounding 
antineoplastic drugs: a survey of nurses and pharmacy practitioners. J Occup Environ Hyg 2015; 12: 
588–602. [PubMed: 25897702] 
10. Turci R, Sottani C, Spagnoli G, et al. Biological and environmental monitoring of hospital 
personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt 
Technol Biomed Life Sci 2003; 789: 169–209.
11. Sottani C, Tranfo G, Bettinelli M, et al. Trace determination of anthracyclines in urine: a new high-
performance liquid chromatography/tandem mass spectrometry method for assessing exposure of 
hospital personnel. Rapid Commun Mass Spectrom 2004; 18: 2426–2436. [PubMed: 15386628] 
12. Sottani C, Tranfo G, Faranda P, et al. Highly sensitive high-performance liquid chromatography/
selective reaction monitoring mass spectrometry method for the determination of 
cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents. 
Rapid Commun Mass Spectrom 2005; 19: 2794–800. [PubMed: 16144038] 
13. Sottani C, Rinaldi P, Leoni E, et al. Simultaneous determination of cyclophosphamide, ifosfamide, 
doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid 
chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method 
validation. Rapid Commun Mass Spectrom 2008; 22: 2645–2659. [PubMed: 18666202] 
14. Pieri M, Castiglia L, Basilicata P, et al. Biological monitoring of nurses exposed to doxorubicin 
and epirubicin by a validated liquid chromatography/fluorescence detection method. Ann Occup 
Hyg 2010; 54: 368–376. [PubMed: 20466744] 
15. Nussbaumer S, Fleury-Souverain S, Antinori P, et al. Simultaneous quantification of ten cytotoxic 
drugs by a validated LC-ESI-MS/MS method. Anal Bioanal Chem 2010; 398: 3033–3042. 
[PubMed: 20927508] 
16. Ndaw S, Denis F, Marsan P, et al. Biological monitoring of occupational exposure to 5-
fluorouracil: urinary alpha-fluoro-beta-alanine assay by high performance liquid chromatography 
tandem mass spectrometry in health care personnel. J Chromatogr B Analyt Technol Biomed Life 
Sci 2010; 878: 2630–2634.
17. Fabrizi G, Fioretti M, Rocca LM, et al. DESI-MS2: a rapid and innovative method for trace 
analysis of six cytostatic drugs in health care setting. Anal Bioanal Chem 2012; 403: 973–983. 
[PubMed: 22200922] 
18. Nussbaumer S, Geiser L, Sadeghipour F, et al. Wipe sampling procedure coupled to LC-MS/MS 
analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. Anal 
Bioanal Chem 2012; 402: 2499–2509. [PubMed: 21701850] 
19. Pretty JR, Connor TH, Spasojevic I, et al. Sampling and mass spectrometric analytical methods for 
five antineoplastic drugs in the healthcare environment. J Oncol Pharm Pract 2012; 18: 23–36. 
[PubMed: 21183556] 
20. Vyas N, Yiannakis D, Turner A, et al. Occupational exposure to anti-cancer drugs: a review of 
effects of new technology. J Oncol Pharm Pract 2014; 20: 278–287. [PubMed: 23975555] 
21. B’Hymer C, Connor T, Stinson D, et al. Validation of an HPLC-MS/MS and wipe procedure for 
mitomycin C contamination. J Chromatogr Sci 2015; 53: 619–624. [PubMed: 25129062] 
22. Teschke CY, Hon K, Shen H, et al. Antineoplastic drug contamination in the urine of Canadian 
healthcare workers. Int Arch Occup Environ Health 2015; 88: 933–941. [PubMed: 25626912] 
23. Fabrizi G, Fioretti M and Mainero Rocca L. Dispersive solid phase extraction procedure coupled to 
UPLC-ESI-MS/MS analysis for the simultaneous determination of thirteen cytotoxic drugs in 
human urine. Biomed Chromatogr 2016; 30: 1297–1308. [PubMed: 26762960] 
24. Canal-Raffin M, Khennoufa K, Martinez B, et al. Highly sensitive LC-MS/MS methods for urinary 
biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and 
methotrexate antineoplastic drugs and routine application. J Chromatogr B Analyt Technol 
Biomed Life Sci 2016; pii: S1570–0232(16)31088–1.
Shu et al. Page 9
J Oncol Pharm Pract. Author manuscript; available in PMC 2021 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Kibby T. A review of surface wipe sampling compared to biologic monitoring for occupational 
exposure to antineoplastic drugs. J Occup Environ Hyg 2017; 14: 159–174. [PubMed: 27676216] 
26. Guichard N, Guillarme D, Bonnabry P, et al. Antineoplastic drugs and their analysis: a state of the 
art review. Analyst 2017; 142: 2273–2321. [PubMed: 28560370] 
27. Mathias PI, Connor TH and B’Hymer C. A review of high performance liquid chromatographic-
mass spectrometric urinary methods for anticancer drug exposure of health care workers. J 
Chromatogr B Analyt Technol Biomed Life Sci 2017; 1060: 316–324.
28. Hedmer M, Tinnerberg H, Axmon A, et al. Environmental and biological monitoring of 
antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 
2008; 81: 899–911. [PubMed: 18066576] 
29. Zhou JY, Gao SH, Zhang F, et al. Liquid chromatography-tandem mass spectrometry method for 
simultaneous determination of seven commonly used anticancer drugs in human plasma. J 
Chromatogr B Analyt Technol Biomed Life Sci 2012; 906: 1–8.
30. Friese CR, Yang J, Mendelsohn-Victor K, et al. Randomized controlled trial of an intervention to 
improve nurses’ hazardous drug handling. Oncol Nurs Forum 2019; 46: 248–256. [PubMed: 
30767961] 
31. Schurmann A, Dvorak V, Cruzer C, et al. False-positive liquid chromatography/tandem mass 
spectrometric confirmation of sebuthylazine residues using the identification points system 
according to EU directive 2002/657/EC due to a biogenic insecticide in tarragon. Rapid Commun 
Mass Spectrom 2009; 23: 1196–1200. [PubMed: 19288539] 
32. Bueno MJ, Aguera A, Gomez MJ, et al. Application of liquid chromatography/quadrupole-linear 
Ion trap mass spectrometry and time-of-flight mass spectrometry to the determination of 
pharmaceuticals and related contaminants in wastewater. Anal Chem 2007; 79: 9372–9384. 
[PubMed: 18001124] 
33. Gros M, Petrovic M and Barcelo D. Tracing pharmaceutical residues of different therapeutic 
classes in environmental waters by using liquid chromatography/quadrupole-linear ion trap mass 
spectrometry and automated library searching. Anal Chem 2009; 81: 898–912. [PubMed: 
19113952] 
34. Easty AC, Coakley N, Cheng R, et al. Safe handling of cytotoxics: guideline recommendations. 
Curr Oncol 2015; 22: e27–37. [PubMed: 25684994] 
Shu et al. Page 10
J Oncol Pharm Pract. Author manuscript; available in PMC 2021 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Overlaid MRM chromatograms of 18 chemotherapy drugs at 50 ng/mL in plasma.
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